| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 23.70 | 36 |
| Intrinsic value (DCF) | 1.24 | -93 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 157.80 | 806 |
Nanobiotix S.A. (0QAV.L) is a Paris-based clinical-stage biotechnology company pioneering innovative cancer treatments through its proprietary nanoparticle technology. Specializing in oncology, Nanobiotix's lead product candidate, NBTXR3, is a first-in-class radioenhancer designed to amplify radiotherapy's efficacy for various solid tumors, including soft tissue sarcoma, head and neck cancers, and liver cancers. The company's technology platform leverages hafnium oxide nanoparticles activated by radiotherapy to locally destroy tumors while minimizing damage to healthy tissue. With strategic partnerships like its collaboration with LianBio for commercialization in Asia, Nanobiotix targets high-need oncology markets globally. Operating in the competitive Medical-Pharmaceuticals sector, the company combines cutting-edge nanomedicine with radiotherapy—a $7 billion+ market—positioning itself as a potential disruptor in precision oncology. Despite being pre-revenue, Nanobiotix's Phase III trials and FDA Fast Track designation for NBTXR3 underscore its clinical promise.
Nanobiotix presents a high-risk, high-reward proposition for biotech investors. The company's negative revenue (€-11.6M) and net income (€-68.1M) reflect its clinical-stage status, with cash reserves (€49.7M) needing to sustain operations through critical trial milestones. A beta of 1.52 indicates higher volatility than the market. Investment appeal hinges on NBTXR3's clinical success—positive Phase III results could trigger partnerships or buyout interest, given the unmet need in radio-oncology. However, developmental risks are acute: delayed trials, regulatory hurdles, or competition from immunotherapies could impair valuation. The LianBio partnership mitigates some commercialization risk in Asia. Suitable for speculative investors comfortable with binary biotech outcomes and a 3–5 year horizon.
Nanobiotix competes in the niche intersection of nanomedicine and radiotherapy enhancement—a space with limited direct competitors but surrounded by broader oncology players. Its key differentiator is NBTXR3's physics-based mechanism (radioenhancement via high-Z nanoparticles), avoiding systemic toxicity issues plaguing chemoradiation combos. This positions it as a potential adjunct to standard radiotherapy protocols rather than a replacement. However, the company faces indirect competition from: 1) Immunotherapy leaders (e.g., Merck's Keytruda) dominating IO-radiation combo trials, 2) Targeted radiotherapy players like Fusion Pharma (FUSN) with alpha-particle conjugates, and 3) Conventional radio-sensitizers. Nanobiotix's first-mover advantage in nanoparticle radioenhancement is tempered by scalability challenges and the capital-intensive path to commercialization. Its partnership strategy—exemplified by the LianBio deal—helps offset resource constraints but dilutes economics. The lack of approved products leaves valuation vulnerable to clinical setbacks, though orphan drug designations provide commercial protection if approved. Success hinges on demonstrating superior local control rates versus cheaper radiosensitizers like nimorazole.